CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
REVENUES:
REVENUES	$ 9,161,430	$ 6,462,110	$ 27,978,041	$ 15,186,469
COSTS AND EXPENSES:
Cost of product sales	8,086,849	4,039,696	23,310,710	7,588,137
Research and development expenses	2,042,351	2,796,981	3,696,057	5,660,319
Selling, general and administrative expenses	5,249,980	6,001,353	12,196,250	12,086,422
Impairment, restructuring, severance and related costs	0	1,961,156	3,043,179	2,044,243
TOTAL COSTS AND EXPENSES	15,379,180	14,799,186	42,246,196	27,379,121
LOSS FROM OPERATIONS	(6,217,750)	(8,337,076)	(14,268,155)	(12,192,652)
OTHER EXPENSE:
Interest (expense) income, net	(728,414)	(727,374)	(1,461,976)	(1,439,851)
LOSS BEFORE INCOME TAXES	(6,946,164)	(9,064,450)	(15,730,131)	(13,632,503)
Income tax (expense)/benefit	(279)	65	(6,606)	67,955
NET LOSS	$ (6,946,443)	$ (9,064,385)	$ (15,736,737)	$ (13,564,548)
Basic loss per share (in dollars per share)	$ (0.23)	$ (0.45)	$ (0.52)	$ (0.67)
Diluted loss per share (in dollars per share)	$ (0.23)	$ (0.45)	$ (0.52)	$ (0.67)
Weighted average number of shares outstanding, basic (in shares)	30,222,758	20,219,617	30,156,768	20,191,657
Weighted average number of shares outstanding, diluted (in shares)	30,222,758	20,219,617	30,156,768	20,191,657
Net Product Sales [Member]
REVENUES:
REVENUES	$ 8,858,146	$ 3,931,383	$ 27,385,602	$ 7,956,045
R&D and Grant Revenue [Member]
REVENUES:
REVENUES	8,046	727	26,219	1,107,366
Government Grant Income [Member]
REVENUES:
REVENUES	0	2,280,000	0	5,630,000
License and Royalty Revenue [Member]
REVENUES:
REVENUES	$ 295,238	$ 250,000	$ 566,220	$ 493,058